1
|
Wein AJ. Re: Patterns of Medical Management of Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) in the United States. J Urol 2018. [DOI: 10.1016/j.juro.2018.09.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
2
|
Griebling TL. Re: Efficacy and Safety of Silodosin in the Treatment of Lower Urinary Tract Symptoms in Elderly Men Taking Antihypertensive Medications. J Urol 2018; 200:675-676. [DOI: 10.1016/j.juro.2018.07.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
3
|
Caicedo JI, Taborda A, Robledo D, Bravo-Balado A, Domínguez C, Trujillo CG, Cataño JG, Campos Hernández J, Londoño Trujillo D, Plata M. Photovaporization of the prostate with GreenLight™ laser 180 W XPS versus transurethral resection of the prostate with monopolar energy for the treatment of benign prostatic enlargement: a cost-utility analysis from a healthcare perspective. World J Urol 2018; 37:861-866. [PMID: 30116964 DOI: 10.1007/s00345-018-2425-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2018] [Accepted: 07/25/2018] [Indexed: 10/28/2022] Open
Abstract
PURPOSE To assess the cost-utility of the photovaporization of the prostate (PVP) with GreenLight™ laser 180 W XPS compared to transurethral resection of the prostate with monopolar energy (M-TURP) for lower urinary tract symptoms (LUTS) due to benign prostatic enlargement (BPE) from a healthcare perspective in Colombia. METHODS We designed a Markov model to compare four health states following treatment with either PVP or M-TURP to estimate expected costs and outcomes. We used the results of the only randomized clinical trial published to date comparing PVP versus M-TURP to estimate surgical outcomes, complications, re-operation and re-intervention rates. Time horizon was defined at 2 years with four cycles of 6 months each. Resource-use estimation involved a random selection of clinical records from a local institution and cost list from public healthcare system. Costs were obtained in Colombian pesos and converted to US dollars. Threshold was defined at three-times the Colombian gross domestic product (GDP) per capita. Quality-adjusted-life-years (QALYs) were used based on the utilities of the available literature. Uncertainty was analyzed with deterministic and probabilistic models using a Monte Carlo simulation. RESULTS Patients who underwent PVP gained 1.81 QALYs compared to 1.59 with M-TURP. Costs were US$6797.98 and US$7777.59 for M-TURP and PVP, respectively. Incremental cost-effectiveness ratio was US$4452.81 per QALY, favoring PVP as a cost-effective alternative in our context. CONCLUSIONS In Colombia, with current prices, PVP is cost-effective when compared to M-TURP for LUTS due to BPE for a 2-year time horizon.
Collapse
Affiliation(s)
- Juan Ignacio Caicedo
- Department of Urology, Hospital Universitario Fundación Santa Fe de Bogotá and Universidad de los Andes School of Medicine, Carrera 7 No. 118-09 Piso 3, Clínicas Urológicas, Bogotá D.C., 110111, Colombia.
| | - Alejandra Taborda
- Department of Public Health and Health Economics, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá D.C., Colombia
| | - Daniela Robledo
- Department of Urology, Hospital Universitario Fundación Santa Fe de Bogotá and Universidad de los Andes School of Medicine, Carrera 7 No. 118-09 Piso 3, Clínicas Urológicas, Bogotá D.C., 110111, Colombia
| | - Alejandra Bravo-Balado
- Department of Urology, Hospital Universitario Fundación Santa Fe de Bogotá and Universidad de los Andes School of Medicine, Carrera 7 No. 118-09 Piso 3, Clínicas Urológicas, Bogotá D.C., 110111, Colombia
| | - Cristina Domínguez
- Department of Urology, Hospital Universitario Fundación Santa Fe de Bogotá and Universidad de los Andes School of Medicine, Carrera 7 No. 118-09 Piso 3, Clínicas Urológicas, Bogotá D.C., 110111, Colombia
| | - Carlos Gustavo Trujillo
- Department of Urology, Hospital Universitario Fundación Santa Fe de Bogotá and Universidad de los Andes School of Medicine, Carrera 7 No. 118-09 Piso 3, Clínicas Urológicas, Bogotá D.C., 110111, Colombia
| | - Juan Guillermo Cataño
- Department of Urology, Hospital Universitario Fundación Santa Fe de Bogotá and Universidad de los Andes School of Medicine, Carrera 7 No. 118-09 Piso 3, Clínicas Urológicas, Bogotá D.C., 110111, Colombia
| | - Jonathan Campos Hernández
- Department of Public Health and Health Economics, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá D.C., Colombia
| | - Darío Londoño Trujillo
- Department of Public Health and Health Economics, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá D.C., Colombia
| | - Mauricio Plata
- Department of Urology, Hospital Universitario Fundación Santa Fe de Bogotá and Universidad de los Andes School of Medicine, Carrera 7 No. 118-09 Piso 3, Clínicas Urológicas, Bogotá D.C., 110111, Colombia
| |
Collapse
|
4
|
Anger JT, Goldman HB, Luo X, Carlsson MO, Chapman D, Zou KH, Russell D, Ntanios F, Esinduy CB, Clemens JQ. Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States. Neurourol Urodyn 2017; 37:213-222. [DOI: 10.1002/nau.23276] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2016] [Accepted: 03/08/2017] [Indexed: 11/06/2022]
|